Latest News & Features
Big Pharma
Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza. 13 September 2021
Asia
Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh. 9 September 2021
Americas
Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz. 9 September 2021
Big Pharma
Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide. 9 September 2021
Medtech
Advanced Biologics has managed to convince the English High Court to expedite a patent infringement and validation suit it is embroiled in with German rival Med-El. 9 September 2021
Plant Varieties
International law firm Haynes Boone has launched the CBD Hemp Industry Group to advise businesses on the burgeoning cannabinoid market. 8 September 2021
Americas
Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen. 7 September 2021
Americas
Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market. 7 September 2021
Americas
In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis. 6 September 2021
Medtech
The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial. 2 September 2021